FDA approves Hympavzi for the treatment of adults and adolescents with hemophilia A or B without inhibitors – Pfizer
Pfizer Inc. announced that the FDA has approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12… read more.
